255 results on '"Adoptive cellular immunotherapy"'
Search Results
2. NK-92 cells labeled with Fe3O4-PEG-CD56/Avastin@Ce6 nanoprobes for the targeted treatment and noninvasive therapeutic evaluation of breast cancer
- Author
-
Jingge Lian, Meng Li, Meng Duan, Yaqian Sun, Zilin Wang, Xinyu Guo, Jingchao Li, Guo Gao, and Kangan Li
- Subjects
Multimodal nanomaterials ,NK-92 cells ,Magnetic resonance imaging ,Adoptive cellular immunotherapy ,Photodynamic therapy ,Biotechnology ,TP248.13-248.65 ,Medical technology ,R855-855.5 - Abstract
Abstract Adoptive cellular immunotherapy as a promising and alternative cancer therapy platform is critical for future clinical applications. Natural killer (NK) cells have attracted attention as an important type of innate immune regulatory cells that can rapidly kill multiple adjacent cancer cells. However, these cells are significantly less effective in treating solid tumors than in treating hematological tumors. Herein, we report the synthesis of a Fe3O4-PEG-CD56/Avastin@Ce6 nanoprobe labeled with NK-92 cells that can be used for adoptive cellular immunotherapy, photodynamic therapy and dual-modality imaging-based in vivo fate tracking. The labeled NK-92 cells specifically target the tumor cells, which increases the amount of cancer cell apoptosis in vitro. Furthermore, the in vivo results indicate that the labeled NK-92 cells can be used for tumor magnetic resonance imaging and fluorescence imaging, adoptive cellular immunotherapy, and photodynamic therapy after tail vein injection. These data show that the developed multifunctional nanostructure is a promising platform for efficient innate immunotherapy, photodynamic treatment and noninvasive therapeutic evaluation of breast cancer.
- Published
- 2024
- Full Text
- View/download PDF
3. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.
- Author
-
Yifan Pang and Ghosh, Nilanjan
- Subjects
CELL surface antigens ,T-cell lymphoma ,CD19 antigen ,CHRONIC lymphocytic leukemia ,CHIMERIC antigen receptors ,CHRONIC leukemia - Abstract
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies. Despite the success, treatment failure due to CD19 antigen loss, mutation, or down-regulation remains the main obstacle to cure. On-target, off-tumor effect of CD19-CAR T leads to side effects such as prolonged B-cell aplasia, limiting the application of therapy in indolent diseases such as chronic lymphocytic leukemia (CLL). Alternative CAR targets and multispecific CAR are potential solutions to improving cellular therapy outcomes in BNHL. For Hodgkin lymphoma and T-cell lymphoma, several cell surface antigens have been studied as CAR targets, some of which already showed promising results in clinical trials. Some antigens are expressed by different lymphomas and could be used for designing tumor-agnostic CAR. Here, we reviewed the antigens that have been studied for novel CAR-based therapies, as well as CARs designed to target two or more antigens in the treatment of lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
- Author
-
Zhang, Tingrui, Tai, Zongguang, Miao, Fengze, Zhang, Xinyue, Li, Jiadong, Zhu, Quangang, Wei, Hua, and Chen, Zhongjian
- Subjects
- *
CELLULAR therapy , *CHIMERIC antigen receptors , *TUMOR treatment , *CARDIOVASCULAR system , *HEMATOLOGIC malignancies , *CALCIUM-sensing receptors , *CELL transformation - Abstract
Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors (CARs) is a highly specific anti-tumor immunotherapy that has shown promise in the treatment of hematological malignancies. However, there has been a slow progress toward the treatment of solid tumors owing to the complex tumor microenvironment that affects the localization and killing ability of the CAR cells. Solid tumors with a strong immunosuppressive microenvironment and complex vascular system are unaffected by CAR cell infiltration and attack. To improve their efficacy toward solid tumors, CAR cells have been modified and upgraded by "decorating" and "pruning". This review focuses on the structure and function of CARs, the immune cells that can be engineered by CARs and the transformation strategies to overcome solid tumors, with a view to broadening ideas for the better application of CAR cell therapy for the treatment of solid tumors. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Injectable hydrogels for personalized cancer immunotherapies.
- Author
-
Mohaghegh, Neda, Ahari, Amir, Zehtabi, Fatemeh, Buttles, Claire, Davani, Saya, Hoang, Hanna, Tseng, Kaylee, Zamanian, Benjamin, Khosravi, Safoora, Daniali, Ariella, Kouchehbaghi, Negar Hosseinzadeh, Thomas, Isabel, Serati Nouri, Hamed, Khorsandi, Danial, Abbasgholizadeh, Reza, Akbari, Mohsen, Patil, Rameshwar, Kang, Heemin, Jucaud, Vadim, and Khademhosseini, Ali
- Subjects
T cells ,ANTIGEN presenting cells ,KILLER cells ,HYDROGELS ,IMMUNOTHERAPY ,CELL anatomy ,EXTRACELLULAR matrix ,POLYMERSOMES - Abstract
The field of cancer immunotherapy has shown significant growth, and researchers are now focusing on effective strategies to enhance and prolong local immunomodulation. Injectable hydrogels (IHs) have emerged as versatile platforms for encapsulating and controlling the release of small molecules and cells, drawing significant attention for their potential to enhance antitumor immune responses while inhibiting metastasis and recurrence. IHs delivering natural killer (NK) cells, T cells, and antigen-presenting cells (APCs) offer a viable method for treating cancer. Indeed, it can bypass the extracellular matrix and gradually release small molecules or cells into the tumor microenvironment, thereby boosting immune responses against cancer cells. This review provides an overview of the recent advancements in cancer immunotherapy using IHs for delivering NK cells, T cells, APCs, chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. First, we introduce IHs as a delivery matrix, then summarize their applications for the local delivery of small molecules and immune cells to elicit robust anticancer immune responses. Additionally, we discuss recent progress in IHs systems used for local combination therapy, including chemoimmunotherapy, radio-immunotherapy, photothermal-immunotherapy, photodynamic-immunotherapy, and gene-immunotherapy. By comprehensively examining the utilization of IHs in cancer immunotherapy, this review aims to highlight the potential of IHs as effective carriers for immunotherapy delivery, facilitating the development of innovative strategies for cancer treatment. In addition, we demonstrate that using hydrogel-based platforms for the targeted delivery of immune cells, such as NK cells, T cells, and dendritic cells (DCs), has remarkable potential in cancer therapy. These innovative approaches have yielded substantial reductions in tumor growth, showcasing the ability of hydrogels to enhance the efficacy of immune-based treatments. As cancer immunotherapy continues to expand, the mode of therapeutic agent delivery becomes increasingly critical. This review spotlights the forward-looking progress of IHs, emphasizing their potential to revolutionize localized immunotherapy delivery. By efficiently encapsulating and controlling the release of essential immune components such as T cells, NK cells, APCs, and various therapeutic agents, IHs offer a pioneering pathway to amplify immune reactions, moderate metastasis, and reduce recurrence. Their adaptability further shines when considering their role in emerging combination therapies, including chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. Understanding IHs' significance in cancer therapy is essential, suggesting a shift in cancer treatment dynamics and heralding a novel period of focused, enduring, and powerful therapeutic strategies. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. 纳米药物在肿瘤过继性细胞免疫治疗中的研究进展.
- Author
-
杨 艳1,, 钱汉清, and 马亚军
- Abstract
Tumor adoptive cellular immunotherapy is a new model of tumor immunotherapy. It can induce effective anti ⁃ tumor immune response in patients by infusion the engineered immune cells which are amplified and activated in vitro. However,due to the complex tumor immunosuppressive microenvironment,immune cells are prone to exhaust and difficult to penetrate deep into the tumor, resulting in limited effect in solid tumors. In recent years,nanomaterials have received extensive attention in the field of tumor immunotherapy. Nanomaterials can promote the expansion of immune cells,their survival after in vivo infusion,and their infiltration in tumors,help immune cells to overcome the physical barriers and immunosuppressive microenvironment in solid tumor tissues,and improve the therapeutic effect. In this article,we reviewed the current research progress of the application of nanomedicine in tumor adoptive cellular immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. NK-92 cells labeled with Fe3O4-PEG-CD56/Avastin@Ce6 nanoprobes for the targeted treatment and noninvasive therapeutic evaluation of breast cancer
- Author
-
Lian, Jingge, Li, Meng, Duan, Meng, Sun, Yaqian, Wang, Zilin, Guo, Xinyu, Li, Jingchao, Gao, Guo, and Li, Kangan
- Published
- 2024
- Full Text
- View/download PDF
8. Study protocol: Phase I/II trial of induced HLA-G+ regulatory T cells in patients undergoing allogeneic hematopoietic cell transplantation from an HLA-matched sibling donor
- Author
-
Memnon Lysandrou, Dionysia Kefala, Panayiota Christofi, Nikolaos Savvopoulos, Penelope Georgia Papayanni, Rodanthy Theodorellou, Eleftheria Sagiadinou, Vassiliki Zacharioudaki, Maria Moukouli, Dimitrios Tsokanas, Georgios Karavalakis, Maria Liga, Konstantinos Stavrinos, Anastasia Papadopoulou, Evangelia Yannaki, and Alexandros Spyridonidis
- Subjects
allogeneic hematopoietic cell transplantation ,graft versus host disease ,adoptive cellular immunotherapy ,regulatory T cells ,HLA-G ,hypomethylating agents ,Medicine (General) ,R5-920 - Abstract
Regulatory T-cell (Treg) immunotherapy has emerged as a promising and highly effective strategy to combat graft-versus-host disease (GvHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Both naturally occurring Treg and induced Treg populations have been successfully evaluated in trials illustrating the feasibility, safety, and efficacy required for clinical translation. Using a non-mobilized leukapheresis, we have developed a good manufacturing practice (GMP)-compatible induced Treg product, termed iG-Tregs, that is enriched in cells expressing the potent immunosuppressive human leucocyte antigen-G molecule (HLA-G+). To assess the safety and the maximum tolerable dose (MTD) of iG-Tregs, we conduct a phase I–II, two-center, interventional, dose escalation (3 + 3 design), open-label study in adult patients undergoing allo-HCT from an HLA-matched sibling donor, which serves also as the donor for iG-Treg manufacturing. Herein, we present the clinical protocol with a detailed description of the study rationale and design as well as thoroughly explain every step from patient screening, product manufacturing, infusion, and participant follow-up to data collection, management, and analysis (registered EUDRACT-2021-006367-26).
- Published
- 2023
- Full Text
- View/download PDF
9. Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer
- Published
- 2020
10. Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights
- Author
-
Kole C, Charalampakis N, Tsakatikas S, Frountzas M, Apostolou K, and Schizas D
- Subjects
pancreatic cancer ,immunotherapy ,immune checkpoint inhibitors ,cancer vaccines ,adoptive cellular immunotherapy ,microsatellite instability. ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Christo Kole,1 Nikolaos Charalampakis,2 Sergios Tsakatikas,2 Maximos Frountzas,3 Konstantinos Apostolou,1 Dimitrios Schizas1 1First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, 115 27, Greece; 2Department of Medical Oncology, Metaxa Cancer Hospital, Athens, 185 37, Greece; 3First Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, Hippocration General Hospital, Athens, 115 27, GreeceCorrespondence: Dimitrios Schizas, First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, 115 27, Greece, Tel +306944505917, Fax +302132061766, Email schizasad@gmail.comAbstract: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and fourth most common cause of death in developed countries. Despite improved survival rates after resection combined with adjuvant chemotherapy or neoadjuvant chemotherapy, recurrence still occurs in a high percentage of patients within the first 2 years after resection. Immunotherapy aims to improve antitumor immune responses and reduce toxicity providing a more specific, targeted therapy compared to chemotherapy and has been proved an efficient therapeutic tool for many solid tumors. In this work, we present the latest advances in PDAC treatment using a combination of immunotherapy with other interventions such as chemotherapy and/or radiation both at neoadjuvant and adjuvant setting. Moreover, we outline the role of the tumor microenvironment as a key barrier to immunotherapy efficacy and examine how immunotherapy biomarkers may be used to detect immunotherapy’s response.Keywords: pancreatic cancer, immunotherapy, immune checkpoint inhibitors, cancer vaccines, adoptive cellular immunotherapy, microsatellite instability
- Published
- 2022
11. Generation and functional characterization of a multigene-modified NK101 cell line exerting diverse mechanisms of antitumor action
- Author
-
Injung Hwang, Hyun Tak Jin, Moon Cheol Kang, Tae Yoon Kim, Young Chul Sung, and Sae Won Kim
- Subjects
nk101 cell line ,multiple genetic engineering ,adoptive cellular immunotherapy ,Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Clonal cell line-based, multigene-modified, off-the-shelf NK cell therapeutics are emerging as the new frontier of adoptive cellular immunotherapy. Here, we utilized a newly established NK cell line, NK101, as a backbone to derive multifaceted killer cells armored with various antitumor modalities through repeated cycles of genetic modification and clonal selection. First, NK101 cells were transduced with a tricistronic lentiviral vector expressing CD7, CD28, and cytosine deaminase (CD). The resulting cell line demonstrated enhanced cytotoxicity against B7+ tumors and exerted bystander killing effects on neighboring tumor cells upon 5-FC treatment. Second, engineered NK101 cells were again transduced with a bicistronic vector expressing membrane-bound interleukin-15 (mbIL-15) and dominant negative TGFβ type II receptor (DNTβRII). Ectopic expression of mbIL-15 resulted in further augmentation of lytic activities against all tested target cells by inducing upregulation of multiple activating receptors, while that of DNTβRII allowed the cells to maintain heightened cytotoxicity in the presence of TGFβ. Finally, dual-transduced NK101 cells were modified to express chimeric antigen receptors (CARs) targeting either a solid tumor antigen (EpCAM) or a hematologic tumor antigen (FLT3). The final engineered products not only demonstrated antigen-specific killing activities in vitro but also exerted strong tumor-inhibitory effects in preclinical models of metastatic solid tumor and hematologic malignancy. Notably, combined treatment with 5-FC further enhanced antitumor efficacy of engineered NK101 in the solid tumor model. Our results demonstrate successful generation of multigene-modified NK101 cell therapeutics exerting diverse mechanisms of antitumor action – activation receptor-mediated innate killing, antigen-specific killing, and bystander effect-mediated killing.
- Published
- 2022
- Full Text
- View/download PDF
12. Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.
- Author
-
Chang Y, Chang M, Bao X, and Dong C
- Abstract
Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has obtained Food and Drug Administration (FDA) approval as a treatment for various hematological malignancies, demonstrating promising preclinical efficacy against cancers. However, the intricate and resource-intensive autologous cell processing, encompassing collection, expansion, engineering, isolation, and administration, hamper the efficacy of this therapeutic modality. Furthermore, conventional CAR T therapy is presently confined to addressing solid tumors due to impediments posed by physical barriers, the potential for cytokine release syndrome, and cellular exhaustion induced by the immunosuppressive and heterogeneous tumor microenvironment. Consequently, a strategic integration of adoptive immunotherapy with synergistic multimodal treatments, such as chemotherapy, radiotherapy, and vaccine therapy etc., emerges as a pivotal approach to surmount these inherent challenges. This collaborative strategy holds the key to addressing the limitations delineated above, thereby facilitating the realization of more precise personalized therapies characterized by heightened therapeutic efficacy. Such synergistic strategy not only serves to mitigate the constraints associated with adoptive immunotherapy but also fosters enhanced clinical applicability, thereby advancing the frontiers of therapeutic precision and effectiveness., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
13. Enhancing and stabilization of cord blood regulatory T-cell suppressive function by human mesenchymal stem cell (MSC)-derived exosomes.
- Author
-
Zhang, Juan, Ma, Xiaoqian, Cao, Lu, He, Xing, Li, Sang, Yang, Min, Yang, Cejun, Rong, Pengfei, Yi, Shounan, Ghimire, Kedar, Kong, Xiangfeng, and Wang, Wei
- Subjects
- *
CORD blood , *MESENCHYMAL stem cells , *HUMAN stem cells , *EXOSOMES , *REGULATORY T cells - Abstract
FOXP3+ regulatory T cells (Tregs) are central to maintaining peripheral tolerance and immune homeostasis. They have the potential to be developed as a cellular therapy to treat various clinical ailments such as autoimmune disorders, inflammatory diseases and to improve transplantation outcomes. However, a major question remains whether Tregs can persist and exert their function effectively in a disease state, where a broad spectrum of inflammatory mediators could inactivate Tregs. In this study, we investigated the potential of mesenchymal stem cell (MSC)-derived exosomes to promote and sustain Tregs function. MSC-conditioned media (MSC-CM) cultured Tregs were more suppressive in both polyclonal and allogeneic responses and were resistant to inflammatory stimulation in vitro compared with the controls. A similar enhancement of Treg function was also observed by culturing Tregs with MSC-derived exosomes alone. The enhanced suppressive activity and stability of Treg cultured in MSC-CM was reduced when exosomes were depleted from MSC-CM. We identified that MSC-derived exosomes could upregulate the expression of LC3(II/I), phosphorylate Jak3 and Stat5 to promote Treg survival, and regulate FOXP3 expression in Tregs. Overall, our study demonstrates that MSC-derived exosomes are capable of enhancing Hucb-Tregs function and stability by activating autophagy and Stat5 signalling pathways. Our findings provide a strong rationale for utilizing MSC-derived exosomes as an effective strategy to enhance Treg function, and improve the overall Tregs-based cell therapy landscape. Hucb-Tregs treated with MSC-CM or MSC-derived exosomes were more suppressive and were resistant to inflammatory stimulation. MSC-derived exosomes could activate autophagy and JAK3-Stat5 signalling pathway to promote Treg survival, and regulate FOXP3 expression. MSC-derived exosomes could be an effective strategy to improve the Tregs-based cell therapy landscape. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. 基于HLA-E功能特点的肿瘤免疫治疗新策略.
- Author
-
曹朔文, 刘丹, and 施明
- Subjects
HLA-B27 antigen ,IMMUNE checkpoint inhibitors ,GENE expression ,ARTIFICIAL neural networks ,IMMUNOTHERAPY - Abstract
Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
15. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
- Author
-
Soldierer, Maren, Bister, Arthur, Haist, Corinna, Thivakaran, Aniththa, Cengiz, Sevgi Can, Sendker, Stephanie, Bartels, Nina, Thomitzek, Antonia, Smorra, Denise, Hejazi, Maryam, Uhrberg, Markus, Scheckenbach, Kathrin, Monzel, Cornelia, Wiek, Constanze, Reinhardt, Dirk, Niktoreh, Naghmeh, and Hanenberg, Helmut
- Subjects
KILLER cells ,HEMATOLOGIC malignancies ,GENETIC engineering ,ERGONOMICS ,PRELEUKEMIA ,BLAST injuries ,ACUTE myeloid leukemia ,ANTIGENS ,AZACITIDINE - Abstract
The great clinical success of chimeric antigen receptor (CAR) T cells has unlocked new levels of immunotherapy for hematological malignancies. Genetically modifying natural killer (NK) cells as alternative CAR immune effector cells is also highly promising, as NK cells can be transplanted across HLA barriers without causing graft-versus-host disease. Therefore, off-the-shelf usage of CAR NK cell products might allow to widely expand the clinical indications and to limit the costs of treatment per patient. However, in contrast to T cells, manufacturing suitable CAR NK cell products is challenging, as standard techniques for genetically engineering NK cells are still being defined. In this study, we have established optimal lentiviral transduction of primary human NK cells by systematically testing different internal promoters for lentiviral CAR vectors and comparing lentiviral pseudotypes and viral entry enhancers. We have additionally modified CAR constructs recognizing standard target antigens for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) therapy—CD19, CD33, and CD123—to harbor a CD34-derived hinge region that allows efficient detection of transduced NK cells in vitro and in vivo and also facilitates CD34 microbead-assisted selection of CAR NK cell products to >95% purity for potential clinical usage. Importantly, as most leukemic blasts are a priori immunogenic for activated primary human NK cells, we developed an in vitro system that blocks the activating receptors NKG2D, DNAM-1, NKp30, NKp44, NKp46, and NKp80 on these cells and therefore allows systematic testing of the specific killing of CAR NK cells against ALL and AML cell lines and primary AML blasts. Finally, we evaluated in an ALL xenotransplantation model in NOD/SCID-gamma (NSG) mice whether human CD19 CAR NK cells directed against the CD19+ blasts are relying on soluble or membrane-bound IL15 production for NK cell persistence and also in vivo leukemia control. Hence, our study provides important insights into the generation of pure and highly active allogeneic CAR NK cells, thereby advancing adoptive cellular immunotherapy with CAR NK cells for human malignancies further. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
- Author
-
Maren Soldierer, Arthur Bister, Corinna Haist, Aniththa Thivakaran, Sevgi Can Cengiz, Stephanie Sendker, Nina Bartels, Antonia Thomitzek, Denise Smorra, Maryam Hejazi, Markus Uhrberg, Kathrin Scheckenbach, Cornelia Monzel, Constanze Wiek, Dirk Reinhardt, Naghmeh Niktoreh, and Helmut Hanenberg
- Subjects
human NK cells ,chimeric antigen receptor ,genetic engineering ,lentiviral vectors (LVS) ,adoptive cellular immunotherapy ,transduction ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The great clinical success of chimeric antigen receptor (CAR) T cells has unlocked new levels of immunotherapy for hematological malignancies. Genetically modifying natural killer (NK) cells as alternative CAR immune effector cells is also highly promising, as NK cells can be transplanted across HLA barriers without causing graft-versus-host disease. Therefore, off-the-shelf usage of CAR NK cell products might allow to widely expand the clinical indications and to limit the costs of treatment per patient. However, in contrast to T cells, manufacturing suitable CAR NK cell products is challenging, as standard techniques for genetically engineering NK cells are still being defined. In this study, we have established optimal lentiviral transduction of primary human NK cells by systematically testing different internal promoters for lentiviral CAR vectors and comparing lentiviral pseudotypes and viral entry enhancers. We have additionally modified CAR constructs recognizing standard target antigens for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) therapy—CD19, CD33, and CD123—to harbor a CD34-derived hinge region that allows efficient detection of transduced NK cells in vitro and in vivo and also facilitates CD34 microbead-assisted selection of CAR NK cell products to >95% purity for potential clinical usage. Importantly, as most leukemic blasts are a priori immunogenic for activated primary human NK cells, we developed an in vitro system that blocks the activating receptors NKG2D, DNAM-1, NKp30, NKp44, NKp46, and NKp80 on these cells and therefore allows systematic testing of the specific killing of CAR NK cells against ALL and AML cell lines and primary AML blasts. Finally, we evaluated in an ALL xenotransplantation model in NOD/SCID-gamma (NSG) mice whether human CD19 CAR NK cells directed against the CD19+ blasts are relying on soluble or membrane-bound IL15 production for NK cell persistence and also in vivo leukemia control. Hence, our study provides important insights into the generation of pure and highly active allogeneic CAR NK cells, thereby advancing adoptive cellular immunotherapy with CAR NK cells for human malignancies further.
- Published
- 2022
- Full Text
- View/download PDF
17. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
- Author
-
Li, Sijin, Xia, Yifei, Hou, Rui, Wang, Xu, Zhao, Xuan, Guan, Zhangchun, Ma, Wen, Xu, Yutong, Zhang, Wei, Liu, Dan, Zheng, Junnian, and Shi, Ming
- Subjects
- *
CHIMERIC proteins , *CHIMERIC antigen receptors , *TUMORS - Abstract
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as a potent immunotherapy and has made significant success in hematologic malignancies by eliciting antigen-specific immune responses. However, response rates of CAR-T cell therapy against solid tumors with immunosuppressive microenvironments remain limited. Co-engineering strategies are advancing methods to overcome immunosuppressive barriers and enhance antitumor responses. Here, we engineered an IL-2 mutein co-engineered CAR-T for the improvement of CAR-T cells against solid tumors and the efficient inhibition of solid tumors. We equipped the CAR-T cells with co-expressing both tumor antigen-targeted CAR and a mutated human interleukin-2 (IL-2m), conferring enhanced CAR-T cells fitness in vitro, reshaped immune-excluded TME, enhanced CAR-T infiltration in solid tumors, and improved tumor control without significant systemic toxicity. Overall, this subject demonstrates the universal CAR-T cells armed strategy for the development and optimization of CAR-T cells against solid tumors. • IL2m-CAR-T cells exhibit augmented proliferation in response to antigenic stimulation. • IL2m-CAR-T cells augment in vitro fitness including reduced exhaustion and improved memory characteristic of CAR-T cells. • IL2m-CAR-T cells promote TME remodeling including regulating PD-1 CD8+ T cells, NK, Treg and M2 macrophage. • IL2m-CAR-T cells have superior proliferation and antitumor activity in murine tumor models. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses.
- Author
-
Chhabra, Neeraj and Kennedy, Joseph
- Subjects
- *
MONOCLONAL antibodies , *CELLULAR therapy , *KINASE inhibitors , *CHIMERIC antigen receptors , *CYTOKINE release syndrome , *IMMUNOTHERAPY - Abstract
Immunotherapy for cancer has undergone a rapid expansion in classes, agents, and indications. By utilizing aspects of the body's innate immune system, immunotherapy has improved life expectancy and quality of life for patients with several types of cancer. Adoptive cellular therapies, including chimeric antigen receptor T (CAR T) cell therapy, involve the genetic engineering of patient T cells to allow for targeting of neoplastic cells. Monitoring of patients during the lymphodepletion prior to therapy and following CAR T cell infusion is necessary to detect toxicity of therapy. Specific toxicities include cytokine release syndrome and neurologic toxicity, both of which may be life-threatening. Tocilizumab and/or corticosteroids should be considered for moderate to severe toxicity. Kinase inhibitor toxicity can occur as "on target" effects or "off target" effects to multiple organ systems due to shared protein epitopes. Treatments are organ-specific. Infusion reactions are common during treatment with monoclonal antibodies and treatment is largely supportive. Clinical experience with oncolytic viruses is limited, but local reactions including cellulitis as well as systemic influenza-like syndromes have been seen but are typically mild. Although clinical experience with adverse effects due to newer immunotherapy agents is growing, an up-to-date understanding of their mechanisms and potential toxicities is critical. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
- Author
-
Pearson, Andrew DJ., Rossig, Claudia, Mackall, Crystal, Shah, Nirali N., Baruchel, Andre, Reaman, Gregory, Ricafort, Rosanna, Heenen, Delphine, Bassan, Abraham, Berntgen, Michael, Bird, Nick, Bleickardt, Eric, Bouchkouj, Najat, Bross, Peter, Brownstein, Carrie, Cohen, Sarah Beaussant, de Rojas, Teresa, Ehrlich, Lori, Fox, Elizabeth, and Gottschalk, Stephen
- Subjects
- *
LYMPHOBLASTIC leukemia , *CELL receptors , *DRUG design , *ACUTE myeloid leukemia , *TUMORS in children , *INTERPROFESSIONAL relations , *LYMPHOMAS , *IMMUNOTHERAPY , *CANCER patient medical care - Abstract
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. The aims of the Forum were to summarise the current landscape of CAR T-cell therapy development in paediatrics, too identify current challenges and future directions, with consideration of other immune effector modalities and ascertain the best strategies to accelerate their development and availability to children. Although the effect is of limited duration in about half of the patients, anti-CD19 CAR T-cells produce high response rates in relapsed/refractory BCP-ALL and this has highlighted previously unknown mechanisms of relapse. CAR T-cell treatment as first- or second-line therapy could also potentially benefit patients whose disease has high-risk features associated with relapse and failure of conventional therapies. Identifying patients with very early and early relapse in whom CAR T-cell therapy may replace haematopoietic stem cell transplantation and be definitive therapy versus those in whom it provides a more effective bridge to haematopoietic stem cell transplantation is a very high priority. Development of approaches to improve persistence, either by improving T cell fitness or using more humanised/fully humanised products and co-targeting of multiple antigens to prevent antigen escape, could potentially further optimise therapy. Many differences exist between paediatric B-cell non-Hodgkin lymphomas (B-NHL) and BCP-ALL. In view of the very small patient numbers with relapsed lymphoma, careful prioritisation is needed to evaluate CAR T-cells in children with Burkitt lymphoma, primary mediastinal B cell lymphoma and other NHL subtypes. Combination trials of alternative targets to CD19 (CD20 or CD22) should also be explored as a priority to improve efficacy in this population. Development of CD30 CAR T-cell immunotherapy strategies in patients with relapsed/refractory Hodgkin lymphoma will likely be most efficiently accomplished by joint paediatric and adult trials. CAR T-cell approaches are early in development for AML and T-ALL, given the unique challenges of successful immunotherapy actualisation in these diseases. At this time, CD33 and CD123 appear to be the most universal targets in AML and CD7 in T-ALL. The results of ongoing or planned first-in-human studies are required to facilitate further understanding. There are promising early results in solid tumours, particularly with GD2 targeting cell therapies in neuroblastoma and central nervous system gliomas that represent significant unmet clinical needs. Further understanding of biology is critical to success. The comparative benefits of autologous versus allogeneic CAR T-cells, T-cells engineered with T cell receptors T-cells engineered with T cell receptor fusion constructs, CAR Natural Killer (NK)-cell products, bispecific T-cell engager antibodies and antibody-drug conjugates require evaluation in paediatric malignancies. Early and proactive academia and multi-company engagement are mandatory to advance cellular immunotherapies in paediatric oncology. Regulatory advice should be sought very early in the design and preparation of clinical trials of innovative medicines, for which regulatory approval may ultimately be sought. Aligning strategic, scientific, regulatory, health technology and funding requirements from the inception of a clinical trial is especially important as these are very expensive therapies. The model for drug development for cell therapy in paediatric oncology could also involve a 'later stage handoff' to industry after early development in academic hands. Finally, and very importantly, strategies must evolve to ensure appropriate ease of access for children who need and could potentially benefit from these therapies. • Chimeric antigen receptor T-cell therapy has substantial promise for children and adolescents with cancer. • However, there are biological, clinical and manufacturing challenges. • Strategies must evolve to ensure appropriate access to these novel treatments. • Comparative benefits of chimeric antigen receptor T-cells and all adoptive cell therapies need evaluation. • Strategic, scientific, regulatory, health technology assessment and funding requirements should be aligned. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Identifizierung von Neoantigenen für immuntherapeutische Ansätze.
- Author
-
Bräunlein, Eva and Krackhardt, Angela M.
- Abstract
Copyright of Der Onkologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
21. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control
- Author
-
Gil Cunha De Santis, Dante Mário Langhi Junior, Andreza Feitoza, Alfredo Mendrone Junior, José Mauro Kutner, Dimas Tadeu Covas, Samuel Campanelli Freitas Couto, Renato L. Guerino-Cunha, Maristela Delgado Orellana, and Sílvia Renata Cornelio Parolin Rizzo
- Subjects
Adoptive cellular immunotherapy ,CAR-T cell therapy ,Cryopreservation ,Quality control ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Chimeric antigen receptor T cells (CAR-T), especially against CD19 marker, present in lymphomas and acute B leukemia, enabled a revolution in the treatment of hematologic neoplastic diseases. The manufacture of CAR-T cells requires the adoption of GMP-compatible methods and it demands the collection of mononuclear cells from the patient (or from the donor), generally through the apheresis procedure, T cell selection, activation, transduction and expansion ex vivo, and finally storage, usually cryopreserved, until the moment of their use. An important aspect is the quality control testing of the final product, for example, the characterization of its identity and purity, tests to detect any contamination by microorganisms (bacteria, fungi, and mycoplasma) and its potency. The product thawing and intravenous infusion do not differ much from what is established for the hematopoietic progenitor cell product. After infusion, it is important to check for the presence and concentration of CAR-T cells in the patient's peripheral blood, as well as to monitor their clinical impact, for instance, the occurrence of short-term, such as cytokine release syndrome and neurological complications, and long-term complications, which require patient follow-up for many years.
- Published
- 2021
- Full Text
- View/download PDF
22. Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment.
- Author
-
Yu Z, Shi J, Fang Y, Zhao Y, Xu A, and Li N
- Subjects
- Humans, Tumor Microenvironment immunology, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating transplantation, Neoplasms therapy, Neoplasms immunology, Immunotherapy, Adoptive methods
- Abstract
Cancer is the main cause of global mortality, and thus far, effective therapeutic strategies for cancer treatment are in high demand. Adoptive transfer of tumor‑infiltrating lymphocytes (TILs) represents a promising avenue in immunotherapy for the management of malignancies. The clinical safety and efficacy of TIL‑based therapy have been established through numerous rigorous clinical trials. However, the efficacy of TIL infusion in inducing an anti‑tumor response is limited to a subset of clinical patients with cancer. Therefore, there is an urgent need to develop innovative strategies aimed at enhancing the effectiveness of TIL‑based therapy. In the present review, the developmental history of TIL‑based therapy was systematically summarized and analyzed, while also presenting a unique perspective on enhancing the multi‑dimensional anti‑tumor capabilities of TILs. The insight and conclusions presented in this review may contribute to improving the efficacy of TIL‑based therapy and expediting its development.
- Published
- 2024
- Full Text
- View/download PDF
23. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.
- Author
-
Pang Y and Ghosh N
- Abstract
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies. Despite the success, treatment failure due to CD19 antigen loss, mutation, or down-regulation remains the main obstacle to cure. On-target, off-tumor effect of CD19-CAR T leads to side effects such as prolonged B-cell aplasia, limiting the application of therapy in indolent diseases such as chronic lymphocytic leukemia (CLL). Alternative CAR targets and multi-specific CAR are potential solutions to improving cellular therapy outcomes in B-NHL. For Hodgkin lymphoma and T-cell lymphoma, several cell surface antigens have been studied as CAR targets, some of which already showed promising results in clinical trials. Some antigens are expressed by different lymphomas and could be used for designing tumor-agnostic CAR. Here, we reviewed the antigens that have been studied for novel CAR-based therapies, as well as CARs designed to target two or more antigens in the treatment of lymphoma., Competing Interests: NG has received research funding from Genentech, Pharmacyclics, Bristol Myers Squibb, AbbVie, Morphosys, Gilead/Kite Pharma; served as a consultant/advisor for AbbVie, AstraZeneca, Genentech, Beigene, Janssen, Lilly, Gilead/Kite Pharma, ADC Therapeutics, Novartis, Lava Therapeutics, Incyte. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Pang and Ghosh.)
- Published
- 2024
- Full Text
- View/download PDF
24. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene
- Author
-
IWABUCHI, MINAMI, NARITA, MIWAKO, UCHIYAMA, TAKAYOSHI, IWAYA, SHUNPEI, OIWA, ERI, NISHIZAWA, YOSHINORI, HASHIMOTO, SHIGEO, BONEHILL, AUDE, KASAHARA, NORIYUKI, TAKIZAWA, JUN, and TAKAHASHI, MASUHIRO
- Subjects
Medicinal and Biomolecular Chemistry ,Chemical Sciences ,Clinical Research ,Biotechnology ,Cancer ,Hematology ,Orphan Drug ,Vaccine Related ,Rare Diseases ,Development of treatments and therapeutic interventions ,5.2 Cellular and gene therapies ,Inflammatory and immune system ,Infection ,Antigen Presentation ,Antigens ,Neoplasm ,B7-1 Antigen ,Cell Line ,Tumor ,Coculture Techniques ,Dendritic Cells ,Gene Expression Regulation ,Leukemic ,Genetic Vectors ,HLA-A Antigens ,Humans ,Immunotherapy ,Interferon-gamma ,Interleukin-2 ,Interleukin-7 ,Lentivirus ,Leukemia ,Lymphocytic ,Chronic ,B-Cell ,Lymphocyte Culture Test ,Mixed ,Signal Transduction ,T-Lymphocytes ,Cytotoxic ,Toll-Like Receptor 4 ,Transduction ,Genetic ,WT1 Proteins ,leukemic plasmacytoid dendritic cell line ,PMDC11 ,caTLR4 ,gene transduction ,lentiviral vector ,antigen-specific cytotoxic T lymphocytes ,adoptive cellular immunotherapy ,Biochemistry and Cell Biology ,Oncology & Carcinogenesis ,Medicinal and biomolecular chemistry - Abstract
The aim of the present study was to enhance the efficiency of leukemia immunotherapy by increasing the antigen-specific cytotoxic T lymphocyte-inducing ability of leukemia cells. The leukemic plasmacytoid dendritic cell line PMDC05 containing the HLA-A02/24 antigen, which was previously established in our laboratory (Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan), was used in the present study. It exhibited higher expression levels of CD80 following transduction with lentiviruses encoding the CD80 gene. This CD80-expressing PMDC05 was named PMDC11. In order to establish a more potent antigen-presenting cell for cellular immunotherapy of tumors or severe infections, PMDC11 cells were transduced with a constitutively active (ca) toll-like receptor 4 (TLR4) gene using the Tet-On system (caTLR4-PMDC11). CD8(+) T cells from healthy donors with HLA-A02 were co-cultured with mutant WT1 peptide-pulsed PMDC11, lipopolysaccharide (LPS)-stimulated PMDC11 or caTLR4-PMDC11 cells. Interleukin (IL)-2 (50 IU/ml) and IL-7 (10 ng/ml) were added on day three of culture. Priming with mutant WT1 peptide-pulsed PMDC11, LPS-stimulated PMDC11 or caTLR4-PMDC11 cells was conducted once per week and two thirds of the IL-2/IL-7 containing medium was replenished every 3-4 days. Immediately prior to the priming with these various PMDC11 cells, the cultured cells were analyzed for the secretion of interferon (IFN)-γ in addition to the percentage and number of CD8(+)/WT1 tetramer(+) T cells using flow cytometry. caTLR4-PMDC11 cells were observed to possess greater antigen-presenting abilities compared with those of PMDC11 or LPS-stimulated PMDC11 cells in a mixed leukocyte culture. CD8 T cells positive for the WT1 tetramer were generated following 3-4 weeks of culture and CD8(+)/WT1 tetramer+ T cells were markedly increased in caTLR4-PMDC11-primed CD8(+) T cell culture compared with PMDC11 or LPS-stimulated PMDC11-primed CD8(+) T cell culture. These CD8(+) T cells co-cultured with caTLR4-PMDC11 cells were demonstrated to secrete IFN-γ and to be cytotoxic to WT1-expressing target cells. These data suggested that the antigen-specific cytotoxic T lymphocyte (CTL)-inducing ability of PMDC11 was potentiated via transduction of the caTLR4 gene. The present study also suggested that caTLR4-PMDC11 cells may be applied as potent antigen-presenting cells for generating antigen-specific CTLs in adoptive cellular immunotherapy against tumors and severe viral infections.
- Published
- 2015
25. Perspectives on Immunotherapy of Metastatic Colorectal Cancer.
- Author
-
Dai, Yongjiu, Zhao, Wenhu, Yue, Lei, Dai, Xinzheng, Rong, Dawei, Wu, Fan, Gu, Jian, and Qian, Xiaofeng
- Subjects
COLORECTAL cancer ,IMMUNOTHERAPY ,METASTASIS ,LIVER metastasis ,PROGNOSIS ,DNA mismatch repair - Abstract
Colorectal cancer, especially liver metastasis, is still a challenge worldwide. Traditional treatment such as surgery, chemotherapy and radiotherapy have been difficult to be further advanced. We need to develop new treatment methods to further improve the poor prognosis of these patients. The emergence of immunotherapy has brought light to mCRC patients, especially those with dMMR. Based on several large trials, some drugs (pembrolizumab, nivolumab) have been approved by US Food and Drug Administration to treat the patients diagnosed with dMMR tumors. However, immunotherapy has reached a bottleneck for other MSS tumors, with low response rate and poor PFS and OS. Therefore, more clinical trials are underway toward mCRC patients, especially those with MSS. This review is intended to summarize the existing clinical trials to illustrate the development of immunotherapy in mCRC patients, and to provide a new thinking for the direction and experimental design of immunotherapy in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications
- Author
-
Ahmet Murat Aydin, Brittany L. Bunch, Matthew Beatty, Ali Hajiran, Jasreman Dhillon, Amod A. Sarnaik, Shari Pilon-Thomas, and Michael A. Poch
- Subjects
adoptive cellular immunotherapy ,Bacillus Calmette–Guerin ,molecular subtypes ,bladder cancer ,tumor-infiltrating lymphocytes ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Tumor infiltrating lymphocytes (TIL) therapy was shown to provide durable objective response in patients with metastatic melanoma. As a fundamental first step to bring TIL therapy to clinical use, identification of patients whose tumors yield optimal numbers of reactive TIL is indispensable. We have previously shown that expansion of tumor reactive TIL from primary bladder tumors and lymph node metastases is feasible. Here, we performed TIL harvesting from additional surgical specimens (additional 31 primary tumors and 10 lymph nodes) to generate a heterogenous cohort of 53 patients with bladder cancer (BC) to evaluate the tumor characteristics that lead to tumor-reactive TIL expansion. Among a total of 53 patients, overall TIL growth from tumor samples were 37/53 (69.8%) and overall anti-tumor reactive TIL were 26/35 (74.3%). Mixed urothelial carcinoma is associated with higher anti-tumor reactivity of expanded TIL than pure urothelial carcinoma (89.5% vs. 56.3%, p=0.049). The anti-tumor reactivity of expanded TIL from primary tumors previously treated with BCG immunotherapy were lower (33.3% vs. 82.6%, p=0.027) although T-cell phenotype (CD3+, CD4+, CD8+, and CD56+) was similar regardless prior of BCG therapy. Addition of agonistic 4-1BB antibody in culture media with IL-2 improved the number of expanded TIL from primary tumors previously treated with BCG immunotherapy. There was no significant difference between basal and luminal subtype tumors in terms of viable and reactive TIL growth. Our study demonstrates that TIL expansion is feasible across all BC patients and BC subtypes, and we suggest that TIL therapy can be a reasonable treatment strategy for various manifestations of BC.
- Published
- 2021
- Full Text
- View/download PDF
27. Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy
- Author
-
Duo Yang, Xiaoli Wang, Xinna Zhou, Jing Zhao, Huabing Yang, Shuo Wang, Michael A. Morse, Jiangping Wu, Yanhua Yuan, Sha Li, Amy Hobeika, Herbert Kim Lyerly, and Jun Ren
- Subjects
blood microbiome ,adoptive cellular immunotherapy ,colorectal cancer ,Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Human microbiota influence the response of malignancies to treatment with immune checkpoint blockade; however, their impact on other forms of immunotherapy is poorly understood. This study explored the effect of blood microbiota on clinical efficacy, represented by progression-free survival (PFS) and overall survival (OS), of combined chemotherapy and adoptive cellular therapy (ACT) in advanced colon cancer patients. Plasma was collected from colorectal cancer patients (CRC) treated with either chemotherapy alone (oxaliplatin and capecitabine) (XELOX CT alone group, n = 19), or ACT with a mixed dendritic cell/cytokine-induced killer cell product (DC-CIK) + XELOX (ICT group, n = 20). Circulating microbiota analysis was performed by PCR amplification and next-generation sequencing of variable regions V3~V4 of bacterial 16S rRNA genes. The association of the blood microbial diversity with clinical response to the therapy as measured by RECIST1.1 and OS was evaluated. The baseline Chao index of blood microbial diversity predicted prolonged PFS and OS of DC/CIK immunotherapy. More diverse blood microbiota that included Bifidobacterium, Lactobacillus, and Enterococcus were identified among responders to DC/CIK compared with non-responders. The plasma bacterial DNA copy number is inversely correlated with the CD3−/CD16+/CD56+ NK cells in circulation and decreased following DC-CIK; however, the Chao index of plasma microbiota significantly increased after administration of the DC-CIK product and this subsequent change was correlated with the number of CD3−/CD16+/CD56+ and CD8+/CD28+ cells infused. The diversity of the blood microbiome is a promising predictive marker for clinical responses to chemotherapy combined with DC-CIK. Cellular immunotherapy can affect the plasma microbiota’s diversity in a manner favorable to clinical responses.
- Published
- 2021
- Full Text
- View/download PDF
28. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications.
- Author
-
Aydin, Ahmet Murat, Bunch, Brittany L., Beatty, Matthew, Hajiran, Ali, Dhillon, Jasreman, Sarnaik, Amod A., Pilon-Thomas, Shari, and Poch, Michael A.
- Subjects
LYMPHOCYTES ,LYMPHATIC metastasis ,TRANSITIONAL cell carcinoma ,TUMORS - Abstract
Tumor infiltrating lymphocytes (TIL) therapy was shown to provide durable objective response in patients with metastatic melanoma. As a fundamental first step to bring TIL therapy to clinical use, identification of patients whose tumors yield optimal numbers of reactive TIL is indispensable. We have previously shown that expansion of tumor reactive TIL from primary bladder tumors and lymph node metastases is feasible. Here, we performed TIL harvesting from additional surgical specimens (additional 31 primary tumors and 10 lymph nodes) to generate a heterogenous cohort of 53 patients with bladder cancer (BC) to evaluate the tumor characteristics that lead to tumor-reactive TIL expansion. Among a total of 53 patients, overall TIL growth from tumor samples were 37/53 (69.8%) and overall anti-tumor reactive TIL were 26/35 (74.3%). Mixed urothelial carcinoma is associated with higher anti-tumor reactivity of expanded TIL than pure urothelial carcinoma (89.5% vs. 56.3%, p=0.049). The anti-tumor reactivity of expanded TIL from primary tumors previously treated with BCG immunotherapy were lower (33.3% vs. 82.6%, p=0.027) although T-cell phenotype (CD3+, CD4+, CD8+, and CD56+) was similar regardless prior of BCG therapy. Addition of agonistic 4-1BB antibody in culture media with IL-2 improved the number of expanded TIL from primary tumors previously treated with BCG immunotherapy. There was no significant difference between basal and luminal subtype tumors in terms of viable and reactive TIL growth. Our study demonstrates that TIL expansion is feasible across all BC patients and BC subtypes, and we suggest that TIL therapy can be a reasonable treatment strategy for various manifestations of BC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. 实体肿瘤TCR-T治疗研究的现状与面临的挑战.
- Author
-
叶春梅 and 叶韵斌
- Abstract
Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
30. A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells
- Author
-
Naomi C. Bosch, Lena-Marie Martin, Caroline J. Voskens, Carola Berking, Barbara Seliger, Gerold Schuler, Niels Schaft, and Jan Dörrie
- Subjects
adoptive cellular immunotherapy ,IL-15 ,natural killer cell ,dendritic cell ,NF-κB ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Natural killer (NK) cells, members of the innate immune system, play an important role in the rejection of HLA class I negative tumor cells. Hence, a therapeutic vaccine, which can activate NK cells in addition to cells of the adaptive immune system might induce a more comprehensive cellular response, which could lead to increased tumor elimination. Dendritic cells (DCs) are capable of activating and expanding NK cells, especially when the NFκB pathway is activated in the DCs thereby leading to the secretion of the cytokine IL-12. Another prominent NK cell activator is IL-15, which can be bound by the IL-15 receptor alpha-chain (IL-15Rα) to be transpresented to the NK cells. However, monocyte-derived DCs do neither secrete IL-15, nor express the IL-15Rα. Hence, we designed a chimeric protein consisting of IL-15 and the IL-15Rα. Upon mRNA electroporation, the fusion protein was detectable on the surface of the DCs, and increased the potential of NFκB-activated, IL-12-producing DC to activate NK cells in an autologous cell culture system with ex vivo-generated cells from healthy donors. These data show that a chimeric IL-15/IL-15Rα molecule can be expressed by monocyte-derived DCs, is trafficked to the cell surface, and is functional regarding the activation of NK cells. These data represent an initial proof-of-concept for an additional possibility of further improving cellular DC-based immunotherapies of cancer.
- Published
- 2021
- Full Text
- View/download PDF
31. Thapsigargin-Stimulated LAD2 Human Mast Cell Line Is a Potent Cellular Adjuvant for the Maturation of Monocyte-Derived Dendritic Cells for Adoptive Cellular Immunotherapy
- Author
-
Pavla Taborska, Dmitry Stakheev, Jirina Bartunkova, and Daniel Smrz
- Subjects
LAD2 human mast cells ,dendritic cells ,maturation ,adoptive cellular immunotherapy ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The preparation of dendritic cells (DCs) for adoptive cellular immunotherapy (ACI) requires the maturation of ex vivo-produced immature(i) DCs. This maturation ensures that the antigen presentation triggers an immune response towards the antigen-expressing cells. Although there is a large number of maturation agents capable of inducing strong DC maturation, there is still only a very limited number of these agents approved for use in the production of DCs for ACI. In seeking novel DC maturation agents, we used differentially activated human mast cell (MC) line LAD2 as a cellular adjuvant to elicit or modulate the maturation of ex vivo-produced monocyte-derived iDCs. We found that co-culture of iDCs with differentially activated LAD2 MCs in serum-containing media significantly modulated polyinosinic:polycytidylic acid (poly I:C)-elicited DC maturation as determined through the surface expression of the maturation markers CD80, CD83, CD86, and human leukocyte antigen(HLA)-DR. Once iDCs were generated in serum-free conditions, they became refractory to the maturation with poly I:C, and the LAD2 MC modulatory potential was minimized. However, the maturation-refractory phenotype of the serum-free generated iDCs was largely overcome by co-culture with thapsigargin-stimulated LAD2 MCs. Our data suggest that differentially stimulated mast cells could be novel and highly potent cellular adjuvants for the maturation of DCs for ACI.
- Published
- 2021
- Full Text
- View/download PDF
32. In Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies
- Author
-
Kevin G. Haworth, Christina Ironside, Zachary K. Norgaard, Willimark M. Obenza, Jennifer E. Adair, and Hans-Peter Kiem
- Subjects
Immunotherapy ,chimeric antigen receptor ,CAR ,mouse model ,adoptive cellular immunotherapy ,ACI ,NSG ,T cell therapy ,HIV ,MATCH mice ,Genetics ,QH426-470 ,Cytology ,QH573-671 - Abstract
Adoptive cellular immunotherapy is a promising and powerful method for the treatment of a broad range of malignant and infectious diseases. Although the concept of cellular immunotherapy was originally proposed in the 1990s, it has not seen successful clinical application until recent years. Despite significant progress in creating engineered receptors against both malignant and viral epitopes, no efficient preclinical animal models exist for rapidly testing and directly comparing these engineered receptors. The use of matured human T cells in mice usually leads to graft-versus-host disease (GvHD), which severely limits the effectiveness of such studies. Alternatively, adult apheresis CD34+ cells engraft in neonatal non-obese diabetic (NOD)-severe combined immunodeficiency (SCID)-common γ chain–/– (NSG) mice and lead to the development of CD3+ T cells in peripheral circulation. We demonstrate that these in vivo murine-matured autologous CD3+ T cells from humans (MATCH) can be collected from the mice, engineered with lentiviral vectors, reinfused into the mice, and detected in multiple lymphoid compartments at stable levels over 50 days after injection. Unlike autologous CD3+ cells collected from human donors, these MATCH mice did not exhibit GvHD after T cell administration. This novel mouse model offers the opportunity to screen different immunotherapy-based treatments in a preclinical setting.
- Published
- 2017
- Full Text
- View/download PDF
33. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
- Author
-
Weilei Hu, Guosheng Wang, Dongsheng Huang, Meihua Sui, and Yibing Xu
- Subjects
cancer immunotherapy ,natural killer cell ,cytokines ,antibodies ,adoptive cellular immunotherapy ,chimeric antigen receptor ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Cancer immunotherapy has been firmly established as a new milestone for cancer therapy, with the development of multiple immune cells as therapeutic tools. Natural killer (NK) cells are innate immune cells endowed with potent cytolytic activity against tumors, and meanwhile act as regulatory cells for the immune system. The efficacy of NK cell-mediated immunotherapy can be enhanced by immune stimulants such as cytokines and antibodies, and adoptive transfer of activated NK cells expanded ex vivo. In addition, NK cells can arm themselves with chimeric antigen receptors (CARs), which may greatly enhance their anti-tumor activity. Most recently, extracellular vesicles (EVs) derived from NK cells show promising anti-tumor effects in preclinical studies. Herein, we carefully review the current progress in these NK cell-based immunotherapeutic strategies (NK cells combined with stimulants, adoptive transfer of NK cells, CAR-NK cells, and NK EVs) for the treatment of cancers, and discussed the challenges and opportunities for opening a new horizon for cancer immunotherapy.
- Published
- 2019
- Full Text
- View/download PDF
34. Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells
- Author
-
John P. Murad, Anna K. Kozlowska, Hee Jun Lee, Maya Ramamurthy, Wen-Chung Chang, Paul Yazaki, David Colcher, John Shively, Mihaela Cristea, Stephen J. Forman, and Saul J. Priceman
- Subjects
chimeric antigen receptor ,ovarian cancer ,regional intraperitoneal delivery ,TAG72 ,tumor-associated glycoproteins ,adoptive cellular immunotherapy ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Impressive clinical efficacy of chimeric antigen receptor (CAR)-engineered T cell therapy for hematological malignancies have prompted significant efforts in achieving similar responses in solid tumors. The lack of truly restricted and uniform expression of tumor-associated antigens, as well as limited T cell persistence and/or tumor trafficking pose major challenges for successful translation of CAR T cell therapy in solid tumors. Recent studies have demonstrated that aberrantly glycosylated cell surface proteins on tumor cells are amenable CAR targets. Tumor-associated glycoprotein 72 (TAG72) antigen is the sialyl-Tn found on multiple O-glycoproteins expressed at high levels on the surface of several cancer types, including ovarian cancer. Here, we developed a humanized TAG72-specific CAR containing a 4-1BB intracellular co-stimulatory signaling domain (TAG72-BBζ). TAG72-BBζ CAR T cells showed potent antigen-dependent cytotoxicity and cytokine production against multiple TAG72+ ovarian cancer cell lines and patient-derived ovarian cancer ascites. Using in vivo xenograft models of peritoneal ovarian tumors, regional intraperitoneal delivery of TAG72-BBζ CAR T cells significantly reduced tumor growth, extended overall survival of mice, and was further improved with repeat infusions of CAR T cells. However, reduced TAG72 expression was observed in early recurring tumors, which coincided with a lack of T cell persistence. Taken together, we demonstrate efficacy with TAG72-CAR T cells in ovarian cancer, warranting further investigations as a CAR T cell therapeutic strategy for this disease.
- Published
- 2018
- Full Text
- View/download PDF
35. Stability Analysis of a Mathematical Model for Glioma-Immune Interaction under Optimal Therapy.
- Author
-
Khajanchi, Subhas
- Subjects
- *
MATHEMATICAL analysis , *MATHEMATICAL models , *DRUG side effects , *OPTIMAL control theory , *ORDINARY differential equations - Abstract
We investigate a mathematical model using a system of coupled ordinary differential equations, which describes the interplay of malignant glioma cells, macrophages, glioma specific CD8+T cells and the immunotherapeutic drug Adoptive Cellular Immunotherapy (ACI). To better understand under what circumstances the glioma cells can be eliminated, we employ the theory of optimal control. We investigate the dynamics of the system by observing biologically feasible equilibrium points and their stability analysis before administration of the external therapy ACI. We solve an optimal control problem with an objective functional which minimizes the glioma cell burden as well as the side effects of the treatment. We characterize our optimal control in terms of the solutions to the optimality system, in which the state system coupled with the adjoint system. Our model simulation demonstrates that the strength of treatment u 1 (t) $u_{1}(t)$ plays an important role to eliminate the glioma cells. Finally, we derive an optimal treatment strategy and then solve it numerically. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
- Author
-
Hu, Weilei, Wang, Guosheng, Huang, Dongsheng, Sui, Meihua, and Xu, Yibing
- Subjects
CANCER immunotherapy ,KILLER cells ,CELLULAR signal transduction ,CANCER cells ,IMMUNE system ,CYTOTOXIC T cells - Abstract
Cancer immunotherapy has been firmly established as a new milestone for cancer therapy, with the development of multiple immune cells as therapeutic tools. Natural killer (NK) cells are innate immune cells endowed with potent cytolytic activity against tumors, and meanwhile act as regulatory cells for the immune system. The efficacy of NK cell-mediated immunotherapy can be enhanced by immune stimulants such as cytokines and antibodies, and adoptive transfer of activated NK cells expanded ex vivo. In addition, NK cells can arm themselves with chimeric antigen receptors (CARs), which may greatly enhance their anti-tumor activity. Most recently, extracellular vesicles (EVs) derived from NK cells show promising anti-tumor effects in preclinical studies. Herein, we carefully review the current progress in these NK cell-based immunotherapeutic strategies (NK cells combined with stimulants, adoptive transfer of NK cells, CAR-NK cells, and NK EVs) for the treatment of cancers, and discussed the challenges and opportunities for opening a new horizon for cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Immunotherapy: Current Status and Future Perspectives.
- Author
-
Floudas, Charalampos S., Brar, Gagandeep, and Greten, Tim F.
- Subjects
- *
IMMUNOTHERAPY , *SMALL molecules , *PROTEIN-tyrosine kinases , *HEPATOCELLULAR carcinoma , *CELLULAR therapy - Abstract
Hepatocellular carcinoma (HCC) has an increasing incidence and dismal prognosis, with few systemic treatments approved, including several small molecule tyrosine kinase inhibitors. The application of immune checkpoint inhibitors (ICIs) to HCC has resulted in durable activity, and further evaluation is ongoing. In this review, we discuss the immunologic principles and the mechanism of action of the ICIs and present the relevant clinical data. Furthermore, we provide an overview of the current and emerging immunotherapeutic approaches for HCC, such as combination treatments, vaccines, and cellular therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy.
- Author
-
Riegler, Lara L, Jones, Gavin P, and Lee, Daniel W
- Subjects
- *
CHIMERIC antigen receptors , *LYMPHOBLASTIC leukemia , *T cells , *GRADING of students , *ACUTE leukemia - Abstract
With immunotherapy innovations for cancer treatment, in particular chimeric antigen receptor (CAR) T cells, becoming more successful and prevalent, strategies to mitigate and manage their toxicities are required. Anti-CD19 CAR T-cell therapy has revolutionized the treatment of relapsed/refractory pediatric and adult acute lymphoblastic leukemia and refractory adult non-Hodgkin lymphoma, resulting in the expanded use of CAR T cells in multicenter trials and as US FDA-approved products. Cytokine release syndrome (CRS) and CAR-associated neurotoxicity, which can occur independently or concurrently with CRS, are two potentially life-threatening toxicities of CAR T-cell therapy. In this review, we will focus on describing the pathophysiology behind CRS, the proposed definitions of and grading systems for CRS, and innovative options for treating this potentially lethal systemic inflammatory condition. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.
- Author
-
Murad, John P., Kozlowska, Anna K., Lee, Hee Jun, Ramamurthy, Maya, Chang, Wen-Chung, Yazaki, Paul, Colcher, David, Shively, John, Cristea, Mihaela, Forman, Stephen J., and Priceman, Saul J.
- Abstract
Impressive clinical efficacy of chimeric antigen receptor (CAR)-engineered T cell therapy for hematological malignancies have prompted significant efforts in achieving similar responses in solid tumors. The lack of truly restricted and uniform expression of tumor-associated antigens, as well as limited T cell persistence and/or tumor trafficking pose major challenges for successful translation of CAR T cell therapy in solid tumors. Recent studies have demonstrated that aberrantly glycosylated cell surface proteins on tumor cells are amenable CAR targets. Tumor-associated glycoprotein 72 (TAG72) antigen is the sialyl-Tn found on multiple O-glycoproteins expressed at high levels on the surface of several cancer types, including ovarian cancer. Here, we developed a humanized TAG72-specific CAR containing a 4-1BB intracellular co-stimulatory signaling domain (TAG72-BBζ). TAG72-BBζ CAR T cells showed potent antigen-dependent cytotoxicity and cytokine production against multiple TAG72
+ ovarian cancer cell lines and patient-derived ovarian cancer ascites. Using in vivo xenograft models of peritoneal ovarian tumors, regional intraperitoneal delivery of TAG72-BBζ CAR T cells significantly reduced tumor growth, extended overall survival of mice, and was further improved with repeat infusions of CAR T cells. However, reduced TAG72 expression was observed in early recurring tumors, which coincided with a lack of T cell persistence. Taken together, we demonstrate efficacy with TAG72-CAR T cells in ovarian cancer, warranting further investigations as a CAR T cell therapeutic strategy for this disease. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
40. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
- Author
-
Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Michail Vailas, Dimitrios Moris, Efthymios Gkotsis, Stylianos Kykalos, Michalis V. Karamouzis, and Dimitrios Schizas
- Subjects
hepatocellular carcinoma ,immunotherapy ,immune checkpoint inhibitors ,cancer vaccines ,adoptive cellular immunotherapy ,oncolytic viruses ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Hepatocellular carcinoma (HCC) is one of one of the most frequent liver cancers and the fourth leading cause of cancer-related mortality worldwide. Current treatment options such as surgery, neoadjuvant chemoradiotherapy, liver transplantation, and radiofrequency ablation will benefit only a very small percentage of patients. Immunotherapy is a novel treatment approach representing an effective and promising option against several types of cancer. The aim of our study is to present the currently ongoing clinical trials and to evaluate the efficacy of immunotherapy in HCC. In this paper, we demonstrate that combination of different immunotherapies or immunotherapy with other modalities results in better overall survival (OS) and progression-free survival (PFS) compared to single immunotherapy agent. Another objective of this paper is to demonstrate and highlight the importance of tumor microenvironment as a predictive and prognostic marker and its clinical implications in immunotherapy response.
- Published
- 2020
- Full Text
- View/download PDF
41. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control
- Author
-
Dimas Tadeu Covas, Sílvia Renata Cornelio Parolin Rizzo, Dante Mário Langhi Junior, Gil Cunha De Santis, Samuel Campanelli Freitas Couto, Andreza Feitoza, Renato L. Guerino-Cunha, Maristela Delgado Orellana, Alfredo Mendrone Junior, and Jose Mauro Kutner
- Subjects
CAR-T cell therapy ,Cryopreservation ,Adoptive cellular immunotherapy ,biology ,business.industry ,Quality control ,Hematology ,Mycoplasma ,medicine.disease_cause ,medicine.disease ,Peripheral blood mononuclear cell ,Chimeric antigen receptor ,CD19 ,Special Article ,Cytokine release syndrome ,Leukemia ,Immunology ,T cell selection ,biology.protein ,Immunology and Allergy ,Medicine ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,business ,Ex vivo - Abstract
Chimeric antigen receptor T cells (CAR-T), especially against CD19 marker, present in lymphomas and acute B leukemia, enabled a revolution in the treatment of hematologic neoplastic diseases. The manufacture of CAR-T cells requires the adoption of GMP-compatible methods and it demands the collection of mononuclear cells from the patient (or from the donor), generally through the apheresis procedure, T cell selection, activation, transduction and expansion ex vivo, and finally storage, usually cryopreserved, until the moment of their use. An important aspect is the quality control testing of the final product, for example, the characterization of its identity and purity, tests to detect any contamination by microorganisms (bacteria, fungi, and mycoplasma) and its potency. The product thawing and intravenous infusion do not differ much from what is established for the hematopoietic progenitor cell product. After infusion, it is important to check for the presence and concentration of CAR-T cells in the patient's peripheral blood, as well as to monitor their clinical impact, for instance, the occurrence of short-term, such as cytokine release syndrome and neurological complications, and long-term complications, which require patient follow-up for many years.
- Published
- 2021
42. High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells
- Author
-
Francesca Garofano and Ingo G. H. Schmidt-Wolf
- Subjects
cannabidiol ,adoptive cellular immunotherapy ,multiple myeloma ,cytokine-induced killer cells ,endocannabinoid system ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Multiple myeloma (MM) is characterized by aberrant bone marrow plasma cell (PC) proliferation and is one of the most common hematological malignancies. The potential effect of cannabinoids on the immune system and hematological malignancies has been poorly characterized. Cannabidiol (CBD) may be used to treat various diseases. CBD is known to exert immunomodulatory effects through the activation of cannabinoid receptor 2 (CB2), which is expressed in high levels in the hematopoietic system. Cytokine-induced killer (CIK) cells are a heterogeneous population of polyclonal T lymphocytes obtained via ex vivo sequential incubation of peripheral blood mononuclear cells (PBMCs) with interferon-γ (IFN-γ), anti CD3 monoclonal antibody, and IL-2. They are characterized by the expression of CD3+ and CD56+, which are surface markers common to T lymphocytes and natural killer (NK) cells. CIK cells are mainly used in hematological patients who suffer relapse after allogeneic transplantation. Here, we investigated their antitumor effect in combination with pure cannabidiol in KMS-12 MM cells by lactate dehydrogenase LDH cytotoxicity assay, CCK-8 assay, and flow cytometry analysis. The surface and intracellular CB2 expressions on CIK cells and on KMS-12 and U-266 MM cell lines were also detected by flow cytometry. Our findings confirm that the CB2 receptor is highly expressed on CIK cells as well as on MM cells. CBD was able to decrease the viability of tumor cells and can have a protective role for CIK cells. It also inhibits the cytotoxic activity of CIKs against MM at high concentrations, so in view of a clinical perspective, it has to be considered that the lower concentration of 1 µM can be used in combination with CIK cells. Further studies will be required to address the mechanism of CBD modulation of CIK cells in more detail.
- Published
- 2020
- Full Text
- View/download PDF
43. A Mathematical Model of Gene Therapy for the Treatment of Cancer
- Author
-
Tsygvintsev, Alexei, Marino, Simeone, Kirschner, Denise E., Ledzewicz, Urszula, editor, Schättler, Heinz, editor, Friedman, Avner, editor, and Kashdan, Eugene, editor
- Published
- 2013
- Full Text
- View/download PDF
44. High number of PD‐1 positive intratumoural lymphocytes predicts survival benefit of cytokine‐induced killer cells for hepatocellular carcinoma patients.
- Author
-
Chang, Boyang, Shen, Lujun, Wang, Kefeng, Jin, Jietian, Huang, Tao, Chen, Qifeng, Li, Wang, and Wu, Peihong
- Subjects
- *
CYTOKINES , *LIVER cancer , *SURVIVAL behavior (Humans) , *LYMPHOCYTES , *IMMUNOTHERAPY - Abstract
Abstract: Background & Aims: Adjuvant cytokine‐induced killer (CIK) cells treatment has shown potential in reducing the recurrence rate and prolonging the survival of patients with hepatocellular carcinoma (HCC). We aimed to identify the best predictive biomarker for adjuvant CIK cells treatment in patients with HCC after curative resection. Methods: This study retrospectively included 145 pairs of HCC patients by one‐to‐one propensity score matching. One group received CIK cells transfusion after surgery (surgery‐CIK group); the other one group underwent surgery only (surgery‐only group). Immunohistochemistry (IHC) was used to measure PD‐1, PD‐L1, CD4, CD8 and Foxp3 expression in tumour tissues of surgery‐CIK group; IHC of PD‐1 and PD‐L1 was conducted in the surgery‐only group. Results: The surgery‐CIK group had a significantly higher disease‐free survival (DFS) and overall survival (OS) rates compared to the surgery‐only group. Of all the intratumoural biomarkers, in the surgery‐CIK group, multivariate analysis showed that a high number of PD‐1+ tumour infiltrative lymphocytes (TILs) was the only factor that independently predicted favourable OS and DFS. By contrast, in the surgery‐only group, no significant correlations between PD‐1/PD‐L1 expression and survival of patients were identified. Further correlation analysis showed a high number of PD‐1+ TILs associated with a high number of both CD4+ and CD8+ TILs in surgery‐CIK group. Conclusions: A high number of PD‐1+ TILs can serve as a potent biomarker for adopting CIK cells therapy in HCC patients after curative resection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
45. Cytotoxic T‐lymphocyte therapy for post‐transplant lymphoproliferative disorder after solid organ transplantation in children.
- Author
-
Beath, Sue V., Gupte, Girish L., Chiou, Fang Kuan, Wilkie, Gwen M., Vickers, Mark A., and Morland, Bruce
- Subjects
- *
IMMUNOTHERAPY , *LYMPHOPROLIFERATIVE disorders , *T cells , *TRANSPLANTATION of organs, tissues, etc. , *EPSTEIN-Barr virus diseases - Abstract
Abstract: EBV‐CTL immunotherapy targets EBV antigens expressed by tumor cells in PTLD. Data on outcome of EBV‐CTL in pSOT patients are limited. The aim of the study is to describe our experience with allogeneic, third‐party EBV‐CTL for the treatment of PTLD in pSOT patients in a single tertiary center. Retrospective review was performed of all pSOT patients who received EBV‐CTL for PTLD. PTLD was diagnosed using World Health Organization histologic criteria. EBV‐CTLs were derived from human leukocyte antigen‐typed, EBV‐seropositive third‐party donors, and cryopreserved and maintained by an accredited national blood transfusion service. Ten patients received EBV‐CTL for histologically proven PTLD from 1999 to 2016 following liver (n=5), combined intestinal/liver (n=4), and liver/kidney (n=1) transplantation. PTLD occurred at median age of 40 months (range: 12‐144) and median post‐transplant interval of 8 months (range: 2‐107). Seven had monomorphic, two had polymorphic, and one had Hodgkin‐type PTLD. All were of B‐cell origin and EBV‐positive on histology. EBV‐CTL achieved an overall remission rate of 80% (8 of 10). Transient adverse effects included fever, tachycardia, and vomiting. None developed graft‐versus‐host disease or opportunistic infections. EBV‐CTL is an effective treatment for PTLD in pSOT patients, with good remission rate and minimal toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
46. Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer.
- Author
-
JUAN DU, SHU SU, HONGYAN LI, JIE SHAO, FANYAN MENG, MI YANG, HANQING QIAN, ZHENGYUN ZOU, XIAOPING QIAN, and BAORUI LIU
- Subjects
- *
IRRADIATION , *CYTOTOXIC T cells , *IMMUNOTHERAPY , *CHEMOKINES , *IMMUNOGLOBULINS - Abstract
Adoptive cellular immunotherapy (ACI) has been demonstrated to be a promising cancer therapeutic; however, the inefficient migration of adoptive immune cells to tumors is one of the rate-limiting factors of ACI. The present study investigated whether 2 Gy low dose irradiation (LDI) was able to increase the migration of adoptive lymphocytes to gastric cancer cells. Treatment with 2 Gy LDI resulted in marked chemokine (C-X-C motif) ligand 9 (CXCL9) and CXCL10 production from gastric cancer cell lines. A Transwell chamber migration assay demonstrated enhanced transmigration of cytotoxic T lymphocytes to gastric cancer cells following LDI treatment. After 2 Gy LDI application to established gastric carcinoma in nude mice, labeled immune cells were infused by intravenous injection and concentrated fluorescence signals were observed at the tumor sites within the mice, with a peak signal at 8-h LDI. Increased numbers of adoptive T cells at the tumor sites were also observed using flow cytometry. Furthermore, a case study of a patient with metastatic gastric cancer who had received ACI treatment combined with 2 Gy LDI provided further evidence that 2 Gy LDI is able to recruit antitumor effector T cells to tumor sites. Therefore, the ability of 2 Gy LDI to convert tumors into inflamed peripheral tissues may be exploited to overcome obstacles at the effector phase of the antitumor immune response and improve the therapeutic efficacy of immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
47. A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses
- Author
-
Joseph Kennedy and Neeraj Chhabra
- Subjects
Adoptive cellular immunotherapy ,medicine.drug_class ,Health, Toxicology and Mutagenesis ,medicine.medical_treatment ,Review ,Toxicology ,Monoclonal antibody ,Cell therapy ,03 medical and health sciences ,0302 clinical medicine ,Cancer immunotherapy ,Neoplasms ,medicine ,Humans ,Chemotherapy ,030212 general & internal medicine ,business.industry ,Antibodies, Monoclonal ,Cancer ,030208 emergency & critical care medicine ,Immunotherapy ,medicine.disease ,Chimeric antigen receptor ,Oncolytic virus ,Oncolytic Viruses ,Cytokine release syndrome ,Adverse events ,Quality of Life ,Cancer research ,business - Abstract
Immunotherapy for cancer has undergone a rapid expansion in classes, agents, and indications. By utilizing aspects of the body’s innate immune system, immunotherapy has improved life expectancy and quality of life for patients with several types of cancer. Adoptive cellular therapies, including chimeric antigen receptor T (CAR T) cell therapy, involve the genetic engineering of patient T cells to allow for targeting of neoplastic cells. Monitoring of patients during the lymphodepletion prior to therapy and following CAR T cell infusion is necessary to detect toxicity of therapy. Specific toxicities include cytokine release syndrome and neurologic toxicity, both of which may be life-threatening. Tocilizumab and/or corticosteroids should be considered for moderate to severe toxicity. Kinase inhibitor toxicity can occur as “on target” effects or “off target” effects to multiple organ systems due to shared protein epitopes. Treatments are organ-specific. Infusion reactions are common during treatment with monoclonal antibodies and treatment is largely supportive. Clinical experience with oncolytic viruses is limited, but local reactions including cellulitis as well as systemic influenza-like syndromes have been seen but are typically mild. Although clinical experience with adverse effects due to newer immunotherapy agents is growing, an up-to-date understanding of their mechanisms and potential toxicities is critical.
- Published
- 2021
48. Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy
- Author
-
Yangyang Li, Youkun Qian, Bin Li, Zhile Li, and Yicheng Zhu
- Subjects
tumor ,business.industry ,T cell ,medicine.medical_treatment ,Cell ,Normal tissue ,Reviews ,Tumor cells ,Immunotherapy ,Review ,neoantigen ,Adoptive cellular immunotherapy ,medicine.anatomical_structure ,Immune system ,Antigen ,medicine ,Cancer research ,Medicine ,immunotherapy ,business - Abstract
Adoptive cellular immunotherapy harnessing the intrinsic immune system for precise treatment has exhibited preliminary success against malignant tumors. As one of the emerging roles in adoptive cellular immunotherapy, neoantigen‐reactive T cell (NRT) focuses on the antigens expressed only by tumor cells. It exclusively obliterates tumor and spares normal tissues, achieving more satisfying effects. However, the development of NRT immunotherapy remains in a relatively primitive stage. Current challenges include identification of NRTs and maintenance of adoptive cell efficacy in vivo. The possible side effects and other limitations of this treatment also hinder its application. Here, we present an overview of NRT immunotherapy and discuss the progress and challenges as well as the prospects in this promising field., Neoantigen‐reactive T‐cell therapy is a thriving branch of immunotherapy in fighting against cancer. It only attacks tumor cells and spares normal tissue. There are different means to select T cells and various efforts could be made to enhance their in vivo application.
- Published
- 2021
49. Research Progress of Adoptive Cellular Immunotherapy in Hematological Malignancies
- Subjects
Adoptive cellular immunotherapy ,business.industry ,Strategy and Management ,Mechanical Engineering ,Immunology ,Metals and Alloys ,Medicine ,business ,Industrial and Manufacturing Engineering - Published
- 2021
50. Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy
- Author
-
Francesca Garofano, Maria A. Gonzalez-Carmona, Dirk Skowasch, Roland Schmidt-Wolf, Alina Abramian, Stefan Hauser, Christian P. Strassburg, and Ingo G. H. Schmidt-Wolf
- Subjects
adoptive cellular immunotherapy ,Cytokine-induced killer cells ,Dendritic cells ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-induced killer cells (CIKs) are considered to be major cytotoxic immunologic effector cells. Usually cancer cells are able to suppress antitumor responses by secreting immunosuppressive factors. CIKs have significant antitumor activity and are capable of eradicating tumors with few side effects. They are a very encouraging cell population used against hematological and solid tumors, with an inexpensive expansion protocol which could yield to superior clinical outcome in clinical trials employing adoptive cellular therapy combination. In the last decade, clinical protocols have been modified by enriching lymphocytes with CIK cells. They are a subpopulation of lymphocytes characterized by the expression of CD3+ and CD56+ wich are surface markers common to T lymphocytes and natural killer NK cells. CIK cells are mainly used in two diseases: in hematological patients who suffer relapse after allogeneic transplantation and in patients with hepatic carcinoma after surgical ablation to eliminate residual tumor cells. Dendritic cells DCs could play a pivotal role in enhancing the antitumor efficacy of CIKs.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.